Orgenesis inks co-development agreement with Accellix to improve quality control in its cellular therapy system

The agreement allows the company to integrate Accellix’s proprietary sampling and analysis technology into its Point-of-Care platform

Cancer cell
POCare works by collecting, processing and supplying cells for various therapeutic treatments

Orgenesis Inc (NASDAQ:ORGS), a cell and gene therapy company, has signed a co-development agreement with cell analytics company Accellix Inc. 

The agreement allows Orgenesis to integrate Accellix’s proprietary sampling and analysis technology — its optic system, cartridges, reagents and software  — into the company’s Point-of-Care (POCare) cellular therapy platform.

POCare works by collecting, processing and supplying cells for various therapeutic treatments. The idea is to shrink the cost of cell and gene therapy through automation. By integrating Accellix’s technology, Orgenesis can greatly improve its quality control.

READ: Orgenesis realigns resources with internal business transfers to support continued growth

“By partnering with Accellix and integrating its advanced optic technologies, cartridges and software, we believe that this will advance Orgenesis’ processing capabilities for different types of cells for our POCare services and platform,” Orgenesis CEO Vered Caplan said.

“We believe the Orgenesis POCare platform can deliver a transformative option to the cell and gene therapy market that will lower costs in order to potentially bring our autologous therapies to patients in a cost effective, high quality and scalable manner.”

Orgenesis is a biotechnology company based in Germantown, Maryland. In addition to POCare, it also owns a subsidiary, Masthercell Global, which operates a Contract Development and Manufacturing Organization platform, which provides manufacturing and development services for biopharmaceutical companies.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Orgenesis

Price: 5.4 USD

Market: NASDAQ
Market Cap: $118.78 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...



Full interview: Orgenesis signs deal with Accellix, invites Academy Award...

Orgenesis (NASDAQ: ORGS) President and CEO Vered Caplan joined Steve Darling from our Proactive New York studio to discuss the company signing an important co-development deal with Accellix. That company specializes in assay migration and delivery platforms for on-demand process...

on 11/04/2019

2 min read